FindTrial
Sign In

Endotoxin and circulating bacteriome in severe COVID-19 patients

Endotoxin and circulating bacteriome in severe COVID-19 patients

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
TCTR
Registry ID
TCTR20200527001
Enrollment
Unknown
Registered
2020-05-27
Start date
2020-03-13
Completion date
Unknown
Last updated
2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

COVID&#45

Interventions

Patients diagnosed with COVID&#45
19 (confirmed by RT&#45
PCR) pneumonia (confirmed by imaging)
Diagnostic
COVID&#45
19 pneumonia patients

Sponsors

Excellence Center for Critical Care Nephrology, King Chulalongkorn Memorial Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Inclusion criteria

Inclusion criteria: (1) age >18 years (2) confirmed COVID-19 pneumonia (3) had leftover blood samples in biobank

Exclusion criteria

Exclusion criteria: (1) Pregnancy (2) Immunocompromised host

Design outcomes

Primary

MeasureTime frame
Endotoxin level Day 1, 3, 7 Chemiluminescent-based endotoxin activity assay—

Secondary

MeasureTime frame
Circulating bacteriome Day 1, 3, 7 16s RNA gene detection by Illumina MiSeq platform—

Countries

Thailand

Contacts

Public ContactNattachai Srisawat

Excellence Center for Critical Care Nephrology, King Chulalongkorn Memorial Hospital, Faculty of Med

drnattachai@yahoo.com0818361891

Outcome results

None listed

Source: TCTR (via WHO ICTRP) · Data processed: Aug 9, 2026